Clinical Trial Update: Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating everolimus and lenalidomide in relapsed or refractory non-Hodgkin or Hodgkin lymphoma; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Angioimmunoblastic T-cell Lymphoma
• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
• Follicular Lymphoma
• Hepatosplenic T-cell Lymphoma
• Hodgkin Lymphoma
• Mantle Cell Lymphoma
• Mycosis Fungoides Sezary Syndrome
• Nasal Type Extranodal Nk T-cell Lymphoma
• Nodal Marginal Zone B-cell Lymphoma
• Peripheral T-cell Lymphoma
• Post-transplant Lymphoproliferative Disorder
• Splenic Marginal Zone Lymphoma
• T-cell Leukemia Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Everolimus (everolimus)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Mayo Clinic | Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-03-23